Advances in atopic dermatitis and urticaria, 2016

Publication date: Available online 23 June 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Tetsuya Honda, Takashi Nomura, Kenji Kabashima
This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis using human samples revealed different immune profiles between childhood AD and adult AD. Phase III clinical trials of dupilumab, an anti-IL4 receptor alpha antibody, on AD have successfully finished, and dupilumab will appear in clinical practice as the first biologics for AD in 2017. In addition, a novel biologics that targets IL-31 shows promising results in a phase II trial. As for the skin microbiome study, novel insights into the mechanisms of microbial dysbiosis such as the colonization of Staphylococcus aureus, a common feature of AD, were proposed. Regarding CSU, autoreactive CD4⁺ T cells that react to FcεRI were discovered, which may potentially contribute to the development of CSU. These findings give new insights into the pathogenesis of AD and CSU, and will lead to more specific and personalized treatments.



http://ift.tt/2sBGcbJ